An Open-Label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis.

Trial Profile

An Open-Label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Ozoralizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2012 Results will be presented at the 2012 American College of Rheumatology Annual Meeting according to an Ablynx media release.
    • 25 Jun 2012 Results released by Ablynx.
    • 26 Mar 2012 Actual patient number is 266 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top